The company's business model involves exclusive supply and license agreements for products outside the US, while seeking generic product approval in the US to potentially save the healthcare system billions in cost. They have developed a knee joint pain injection that lubricates the joint and relieves mild to moderate knee pain for patients who have failed to respond to non-pharmacologic therapy and simple analgesics. Their first product, GenVisc® 850, is a five injection hyaluronic acid product produced from non-avian source material, and they also offer TriVisc, a three injection hyaluronic acid product. Headquartered in Doylestown, PA, OrthogenRx is an early stage private medical device company focused on the development and commercialization of treatments for musculoskeletal conditions, including osteoarthritis.